Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

PHASE3CompletedINTERVENTIONAL
Enrollment

407

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

September 25, 2024

Study Completion Date

October 16, 2024

Conditions
DyslipidemiasHypercholesterolemiaFamilial HypercholesterolemiaASCVDHigh Cholesterol
Interventions
COMBINATION_PRODUCT

Combination Therapy

tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination

DRUG

Monotherapy obicetrapib

tablet; 10mg obicetrapib

DRUG

Monotherapy ezetimibe

capsule; 10mg ezetimibe

OTHER

Combination Therapy placebo

tablet; no active ingredient

OTHER

Obicetrapib Placebo

tablet; no active ingredient

OTHER

Ezetimibe Placebo

capsule; no active ingredient

Trial Locations (45)

17074

Capital Area Research, Camp Hill

21229

Maryland Cardiovascular Specialists, Baltimore

21804

TidalHealth Peninsula Regional, Inc., Salisbury

23435

Hampton Roads Center for Clinical Research, Suffolk

24541

Spectrum Medical, Inc., Danville

27203

Triad Internal Medicine, Asheboro

27518

Cary Research Group, LLC, Cary

27701

Novant Health Clinical Research, LLC, Charlotte

28204

Novant Health Heart and Vascular Institute, Charlotte

28412

Wilmington Health Associates, Wilmington

28557

Lucas Research, Inc, Morehead City

30024

NSC Research, Johns Creek

30189

North Georgia Clinical Research, Woodstock

30501

Center for Advanced Research and Education, Gainesville

31904

Centricity Research - Columbus, Columbus

32127

Progressive Medical Research, Port Orange

32216

Jacksonville Center for Clinical Research, Jacksonville

37404

Chattanooga Research & Medicine, PLLC, Chattanooga

37849

Cardiovascular Research of Knoxville, Powell

38801

North Mississippi Medical Center, Tupelo

44240

Summit Research Group, LLC, Stow

45227

Metabolic and Atherosclerosis Research Center, Cincinnati

46321

Cardiovascular Research of Northwest Indiana, LLC, Munster

48085

Oakland Medical Research Center, Troy

48912

Sparrow Clinical Research Institute, Lansing

49620

Northern Pines Health Center, Buckley

49770

McClaren Bay Heart and Vascular, Bay City

56303

CentraCare Heart & Vascular Center, Saint Cloud

57701

Monument Health Clinical Research, a department of Monument Health Rapid City Hospital, Inc, Rapid City

60077

Evanston Premier Healthcare Research LLC, Skokie

63136

St. Louis Heart and Vascular Cardiology, St Louis

Washington University School of Medicine, St Louis

70535

Horizon Research Group of Opelousas, Eunice

71111

Grace Research, LLC - Bossier City, LA, Bossier City

75069

Wellness Clinical Research Associates, McKinney

76132

Diabetes and Thyroid Center of Fort Worth, Fort Worth

77030

Baylor College of Medicine, Houston

77054

Juno Research, LLC - Medical Center Office, Houston

77375

DM Clinical Research, Houston

Northwest Houston Heart Center, Tomball

78404

South Texas Clinical Research, Corpus Christi

79109

PharmaTex Research, LLC, Amarillo

79124

Amarillo Heart Clinical Research Institute, Inc, Amarillo

84015

Alpine Research Organization, Inc., Clinton

85297

East Valley Diabetes & Endocrinology, Gilbert

Sponsors
All Listed Sponsors
lead

NewAmsterdam Pharma

INDUSTRY

NCT06005597 - Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies | Biotech Hunter | Biotech Hunter